Disease block
C15-C26 – Bösartige Neubildungen der Verdauungsorgane
- Chapter II: Neubildungen
55Decisions
69Patient groups
Added benefit by patient group
- Major1
- Considerable7
- Minor15
- Non-quantifiable3
- Not proven43
Diseases in this disease block
- C15 Bösartige Neubildung des Ösophagus 17 decisions
- C16 Bösartige Neubildung des Magens 21 decisions
- C17 Bösartige Neubildung des Dünndarmes 9 decisions
- C18 Bösartige Neubildung des Kolons 19 decisions
- C19 Bösartige Neubildung am Rektosigmoid, Übergang 16 decisions
- C20 Bösartige Neubildung des Rektums 16 decisions
- C21 Bösartige Neubildung des Anus und des Analkanals 6 decisions
- C22 Bösartige Neubildung der Leber und der intrahepatischen Gallengänge 19 decisions
- C23 Bösartige Neubildung der Gallenblase 9 decisions
- C24 Bösartige Neubildung sonstiger und nicht näher bezeichneter Teile der Gallenwege 12 decisions
- C25 Bösartige Neubildung des Pankreas 6 decisions
- C26 Bösartige Neubildung sonstiger und ungenau bezeichneter Verdauungsorgane 8 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-10-01ZynyzRetifanlimabMinor
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-08-06ZiiheraZanidatamabNon-quantifiable
- 2026-07-02LoqtorziToripalimabNot proven: 2 of 2 patient groups
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-03-19EnhertuTrastuzumab deruxtecanMinor
- 2025-12-18OpdivoNivolumabMinor
- 2025-12-18OpdivoNivolumabNot proven
- 2025-12-04OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-04-17VyloyZolbetuximabMinor
- 2025-01-16FruzaqlaFruquintinibMinor
- 2024-11-22LytgobiFutibatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-06-20KeytrudaPembrolizumabMinor
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-02-15LonsurfTrifluridin/TipiracilConsiderable
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-10-05ImfinziDurvalumabMinor
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05ImjudoTremelimumabNot proven: 2 of 2 patient groups
- 2023-07-20EnhertuTrastuzumab deruxtecanNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-06-16QinlockRipretinibMajor
- 2022-05-19OpdivoNivolumabConsiderable
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20OpdivoNivolumabNot proven
- 2021-10-07PemazyrePemigatinibNon-quantifiable
- 2021-09-16KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-07-01OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03LynparzaOlaparibNot proven
- 2021-05-20TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-12-17BraftoviEncorafenibConsiderable
- 2020-10-01LonsurfTrifluridin/TipiracilMinor
- 2020-04-02LonsurfTrifluridin/TipiracilMinor
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-02-20CyramzaRamucirumabMinor
- 2019-06-06Cabometyx CabozantinibMinor
- 2019-03-22LenvimaLenvatinibNot proven: 2 of 2 patient groups
- 2016-10-20CyramzaRamucirumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-03-17StivargaRegorafenibNot proven
- 2015-02-19StivargaRegorafenibNot proven
- 2013-08-15ZaltrapAfliberceptMinor
- 2012-12-20TeysunoTegafur/Gimeracil/OteracilNot proven
Data status: 2026-10-29